Fidelity Investments’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-10,693,161
| Closed | -$294M | – | 5353 |
|
|
2021
Q2 | $294M | Buy |
10,693,161
+6,184,100
| +137% | +$122M | 0.02% | 660 |
|
|
2021
Q1 | $74.4M | Sell |
4,509,061
-1,520,500
| -25% | -$34.6M | 0.01% | 1213 |
|
|
2020
Q4 | $111M | Sell |
6,029,561
-387,400
| -6% | -$6.93M | 0.01% | 981 |
|
|
2020
Q3 | $87.3M | Sell |
6,416,961
-1,413,700
| -18% | -$21.8M | 0.01% | 974 |
|
|
2020
Q2 | $140M | Sell |
7,830,661
-425,844
| -5% | -$6.42M | 0.02% | 740 |
|
|
2020
Q1 | $82.3M | Buy |
8,256,505
+218,900
| +3% | +$1.79M | 0.01% | 830 |
|
|
2019
Q4 | $65.4M | Sell |
8,037,605
-116,000
| -1% | -$1.07M | 0.01% | 1086 |
|
|
2019
Q3 | $80.8M | Buy |
8,153,605
+1,296,900
| +19% | +$12.2M | 0.01% | 982 |
|
|
2019
Q2 | $86.6M | Buy |
6,856,705
+85,277
| +1% | +$899K | 0.01% | 978 |
|
|
2019
Q1 | $69M | Buy |
6,771,428
+115
| +0% | +$882 | 0.01% | 1074 |
|
|
2018
Q4 | $50.8M | Buy |
6,771,313
+433,952
| +7% | +$3.18M | 0.01% | 1128 |
|
|
2018
Q3 | $60.8M | Buy |
6,337,361
+23,100
| +0.4% | +$269K | 0.01% | 1164 |
|
|
2018
Q2 | $73.4M | Buy |
+6,314,261
| New | +$76.3M | 0.01% | 1092 |
|
Fidelity Investments's TBIO Position: Q3 2021 in Review
Fidelity Investments sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 10,693,161 shares — an estimated $294M sold.
Fidelity Investments first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $294M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Fidelity Investments reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Fidelity Investments sold 10,693,161 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $294M.
- Fidelity Investments first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- Fidelity Investments's Translate Bio, Inc. Common Stock position peaked at $294M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Fidelity Investments's 13F filing for Q3 2021, filed 15 Nov 2021.